• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRAF V600E与甲状腺乳头状癌中的淋巴结转移

BRAF V600E and lymph node metastases in papillary thyroid cancer.

作者信息

Chen Pan, Pan Liqin, Huang Wensi, Feng Huijuan, Ouyang Wei, Wu Juqing, Wang Jing, Deng Yuying, Luo Jiaxin, Chen Yanying

机构信息

Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China.

出版信息

Endocr Connect. 2020 Oct;9(10):999-1008. doi: 10.1530/EC-20-0420.

DOI:10.1530/EC-20-0420
PMID:33064665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7576641/
Abstract

OBJECTIVE

To evaluate the relationship between the BRAF V600E mutation in lymph node metastasis (LNM) and its invasive characteristics in papillary thyroid cancer (PTC).

MATERIAL AND METHODS

A total of 373 PTC patients were enrolled in this study conducted at Zhujiang Hospital of Southern Medical University between January 2017 and December 2018. PTCs with cervical lymph node metastases were verified pathohistologically, and primary tumors and LNM were examined for the BRAF V600E mutation. Patients were excluded from the study if the BRAF V600E mutation was examined only in primary tumors or only in LNM.

RESULTS

Of the 373 patients examined, BRAF V600E mutation frequency in primary tumors was slightly higher than in LNM (81.5% vs 78.0%, P = 0.000), the intra-class correlation coefficient (ICC) was 0.865 (95% CI 0.835-0.890). The BRAF V600E mutation in both primary tumor and LNM negatively correlated with the size of the largest metastatic focus of LNM (Odds ratio, OR = 0.297, 95% CI 0.143-0.616, P = 0.001; OR = 0.242, 95% CI 0.119-0.492, P = 0.000, respectively). There was no relationship between BRAF V600E mutation in LNM and the number, extranodal extension or stage of LNM (P > 0.05).

CONCLUSION

The BRAF V600E mutation in LNM may not be related to the invasive characteristics of LNM in PTC.

摘要

目的

评估甲状腺乳头状癌(PTC)中淋巴结转移(LNM)的BRAF V600E突变与其侵袭特征之间的关系。

材料与方法

2017年1月至2018年12月在南方医科大学珠江医院进行的这项研究共纳入了373例PTC患者。经病理组织学证实为伴有颈部淋巴结转移的PTC,检测原发肿瘤和LNM中的BRAF V600E突变。如果仅在原发肿瘤或仅在LNM中检测BRAF V600E突变,则将患者排除在研究之外。

结果

在373例接受检查的患者中,原发肿瘤的BRAF V600E突变频率略高于LNM(81.5%对78.0%,P = 0.000),组内相关系数(ICC)为0.865(95%CI 0.835 - 0.890)。原发肿瘤和LNM中的BRAF V600E突变均与LNM最大转移灶的大小呈负相关(优势比,OR = 0.297,95%CI 0.143 - 0.616,P = 0.001;OR = 0.242,95%CI 0.119 - 0.492,P = 0.000)。LNM中的BRAF V600E突变与LNM的数量、结外扩展或分期之间无相关性(P > 0.05)。

结论

LNM中的BRAF V600E突变可能与PTC中LNM的侵袭特征无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46fb/7576641/881c9b994440/EC-20-0420fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46fb/7576641/11c6c6731638/EC-20-0420fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46fb/7576641/881c9b994440/EC-20-0420fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46fb/7576641/11c6c6731638/EC-20-0420fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46fb/7576641/881c9b994440/EC-20-0420fig2.jpg

相似文献

1
BRAF V600E and lymph node metastases in papillary thyroid cancer.BRAF V600E与甲状腺乳头状癌中的淋巴结转移
Endocr Connect. 2020 Oct;9(10):999-1008. doi: 10.1530/EC-20-0420.
2
Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation.BRAF V600E 突变型甲状腺乳头状癌颈部淋巴结转移的危险因素。
Front Endocrinol (Lausanne). 2022 Jun 16;13:884428. doi: 10.3389/fendo.2022.884428. eCollection 2022.
3
Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with Mutation and Clinicopathological Features.具有突变及临床病理特征的甲状腺乳头状癌Ⅴ区淋巴结转移的预测因素
Cancer Manag Res. 2020 May 13;12:3371-3378. doi: 10.2147/CMAR.S247914. eCollection 2020.
4
BRAF Mutation: Has It a Role in Cervical Lymph Node Metastasis of Papillary Thyroid Cancer?BRAF突变:它在甲状腺乳头状癌颈淋巴结转移中起作用吗?
Eur Thyroid J. 2016 Sep;5(3):195-200. doi: 10.1159/000448112. Epub 2016 Aug 20.
5
Predictive Value of BRAF Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.BRAF 突变对甲状腺乳头状癌淋巴结转移的预测价值:Meta 分析。
Curr Med Sci. 2018 Oct;38(5):785-797. doi: 10.1007/s11596-018-1945-7. Epub 2018 Oct 20.
6
BRAF mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account.BRAF突变与所有甲状腺乳头状癌患者的中央淋巴结转移无关:应考虑不同的组织学亚型和术前淋巴结状态。
Oncol Lett. 2017 Oct;14(4):4122-4134. doi: 10.3892/ol.2017.6694. Epub 2017 Aug 1.
7
Serum TSH levels are associated with postoperative recurrence and lymph node metastasis of papillary thyroid carcinoma.血清促甲状腺激素水平与甲状腺乳头状癌术后复发及淋巴结转移相关。
Am J Transl Res. 2021 Jun 15;13(6):6108-6116. eCollection 2021.
8
Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma.甲状腺乳头状癌患者淋巴结转移危险因素的综合评估
Oncol Lett. 2021 Mar;21(3):188. doi: 10.3892/ol.2021.12449. Epub 2021 Jan 6.
9
Younger Than 55 Years Old and V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm.年龄小于55岁和V600E突变是直径≤1.0 cm的乳头状甲状腺癌发生淋巴结转移的危险因素,但在直径>1.0 cm的乳头状甲状腺癌中并非如此。
Int J Gen Med. 2023 Apr 19;16:1403-1414. doi: 10.2147/IJGM.S408588. eCollection 2023.
10
LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.LIMD2 在 BRAF V600E 阳性甲状腺乳头状癌及其配对的淋巴结转移中过表达。
Endocr Pathol. 2018 Sep;29(3):222-230. doi: 10.1007/s12022-018-9526-7.

引用本文的文献

1
Association Between Allele Frequency and Aggressive Behavior in Papillary Thyroid Microcarcinoma.甲状腺微小乳头状癌等位基因频率与侵袭性行为之间的关联
Cancers (Basel). 2025 Aug 1;17(15):2553. doi: 10.3390/cancers17152553.
2
Prediction of contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma based on radiomics.基于影像组学预测单侧甲状腺乳头状癌对侧中央区淋巴结转移
Sci Rep. 2025 Jul 1;15(1):21948. doi: 10.1038/s41598-025-04588-y.
3
Location based BRAF V600E mutation status and dimension patterns of sporadic thyroid nodules: a population-based study.

本文引用的文献

1
Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with Mutation and Clinicopathological Features.具有突变及临床病理特征的甲状腺乳头状癌Ⅴ区淋巴结转移的预测因素
Cancer Manag Res. 2020 May 13;12:3371-3378. doi: 10.2147/CMAR.S247914. eCollection 2020.
2
Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma.BRAF V600E基因突变与甲状腺微小乳头状癌临床病理特征的关系
Int J Clin Exp Pathol. 2019 Sep 1;12(9):3492-3499. eCollection 2019.
3
Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma.
基于位置的BRAF V600E突变状态与散发性甲状腺结节的大小模式:一项基于人群的研究。
BMC Cancer. 2025 Mar 6;25(1):406. doi: 10.1186/s12885-025-13776-y.
4
Papillary Thyroid Carcinoma: Correlation Between Molecular and Clinical Features.甲状腺乳头状癌:分子与临床特征的相关性。
Mol Diagn Ther. 2024 Sep;28(5):601-609. doi: 10.1007/s40291-024-00721-1. Epub 2024 Jun 19.
5
Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.下一代测序鉴定出 RET 变异与甲状腺乳头状癌的淋巴结转移和免疫微环境有关。
BMC Endocr Disord. 2024 May 11;24(1):68. doi: 10.1186/s12902-024-01586-5.
6
Advances in targeted therapy and biomarker research in thyroid cancer.甲状腺癌的靶向治疗和生物标志物研究进展。
Front Endocrinol (Lausanne). 2024 Mar 4;15:1372553. doi: 10.3389/fendo.2024.1372553. eCollection 2024.
7
Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation.甲状腺 BRAF V600E 突变型分化型乳头状癌中肿瘤浸润细胞毒性淋巴细胞的杀伤能力分析及其对淋巴结转移的影响。
Diagn Pathol. 2024 Feb 10;19(1):29. doi: 10.1186/s13000-024-01454-9.
8
Integrating US-guided FNAB, BRAF mutation, and clinicopathologic characteristics to predict cervical central lymph-node metastasis in preoperative patients with cN0 papillary thyroid carcinoma.将 US 引导下的细针穿刺活检、BRAF 突变与临床病理特征相结合,预测术前 cN0 甲状腺乳头状癌患者颈中央区淋巴结转移。
Eur Arch Otorhinolaryngol. 2023 Dec;280(12):5565-5574. doi: 10.1007/s00405-023-08156-w. Epub 2023 Aug 4.
9
Analysis of factors influencing the clinical outcome after surgery and I therapy in patients with moderate-risk thyroid papillary carcinoma.分析中危甲状腺乳头状癌患者手术后及 I 治疗临床转归的影响因素。
Front Endocrinol (Lausanne). 2022 Oct 14;13:1015798. doi: 10.3389/fendo.2022.1015798. eCollection 2022.
10
Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation.BRAF V600E 突变型甲状腺乳头状癌颈部淋巴结转移的危险因素。
Front Endocrinol (Lausanne). 2022 Jun 16;13:884428. doi: 10.3389/fendo.2022.884428. eCollection 2022.
BRAF V600E与甲状腺乳头状癌临床特征之间的关系。
Endocr Connect. 2019 Jul;8(7):988-996. doi: 10.1530/EC-19-0246.
4
SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.最大转移灶至淋巴结的大小与 PN1 期甲状腺乳头状癌不完全缓解相关。
Endocr Pract. 2019 Sep;25(9):887-898. doi: 10.4158/EP-2018-0583. Epub 2019 Jun 6.
5
Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy.BRAFV600E突变在甲状腺乳头状癌中的临床意义及其对放射性碘治疗的影响。
Endocr Connect. 2019 Jun;8(6):754-763. doi: 10.1530/EC-19-0045.
6
The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.VE-1(BRAF V600E相关)抗体的免疫细胞化学表达可在液基细胞学检查中识别甲状腺乳头状癌的侵袭性变体。
Cytopathology. 2019 Sep;30(5):460-467. doi: 10.1111/cyt.12690. Epub 2019 Apr 23.
7
Thyroid surgery for differentiated thyroid cancer - recent advances and future directions.分化型甲状腺癌的甲状腺手术——最新进展和未来方向。
Nat Rev Endocrinol. 2018 Nov;14(11):670-683. doi: 10.1038/s41574-018-0080-7.
8
Cancer incidence and mortality in China, 2014.2014年中国的癌症发病率和死亡率
Chin J Cancer Res. 2018 Feb;30(1):1-12. doi: 10.21147/j.issn.1000-9604.2018.01.01.
9
Clinical Characteristics of Subtypes of Follicular Variant Papillary Thyroid Carcinoma.滤泡型变异型甲状腺癌亚型的临床特征。
Thyroid. 2018 Mar;28(3):311-318. doi: 10.1089/thy.2016.0671. Epub 2018 Feb 16.
10
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.原发性甲状腺癌和转移性疾病中的端粒酶逆转录酶(TERT)、BRAF和NRAS
J Clin Endocrinol Metab. 2017 Jun 1;102(6):1898-1907. doi: 10.1210/jc.2016-2785.